EVALUATING TREATMENT RESPONSE, SURVIVAL OF STAGE IV NON SMALL CELL LUNG CANCER BY PEMETREXED – CARBOPLATIN REGIMEN
Main Article Content
Abstract
Aims: To evaluate response and survival of patients with stage IV Non small cell lung cancer who were treated by Pemetrexed – Carboplatin regimen. Patients and method of study: Retrospective and prospective study on 45 non-small cell lung cancer patients in stage IV treated by Pemetrexed - Carboplatin regimen from August 2018 to August 2021. Results: Median of age 59,2 ± 7,4, male/female: 5,4/1. 39/45 (89,7%) patients completed four cycles, and 30/45 (66,7%) completed six cycles of chemotherapy. Objective response rate is 37,8%; disease control rate is 66,7%. Performance status and age are factors affecting response rate. The mean progression-free survival (PFS) was 7.4 ± 0.3 months, the median PFS was 7.7 months. The mean overall survival (OS) was 20.5 ± 1.9 months, the median OS was 19 months. Conclusion: Pemetrexed- Carboplatin regimen is effective in the treatment of stage IV non small cell lung cancer.
Article Details
Keywords
Non small cell lung cancer, stage IV, Pemetrexed Carboplatin
References
2. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. Dec 1 2005;104(11):2449-56. doi:10.1002/cncr.21480
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jul 20 2008;26(21):3543-51. doi:10.1200/jco.2007.15.0375
4. Ito M, Horita N. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Apr 2019;15(2):e3-e10. doi:10.1111/ ajco.12837
5. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. Jun 6 2007;99(11):847-57. doi:10.1093/jnci/djk196
6. Wang W, Shang L, Li X, Li J, Wen F, Liu J. [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. Jan 2011; 14 (1):54-7. doi:10.3779/j.issn.1009-3419. 2011.01.11
7. Trần Thanh Hà. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng phác đồ pemetrexed – carboplatin tại bệnh viện K. Trường Đại học Y Hà Nội; 2018.
8. Katirtzoglou N, Gkiozos I, Makrilia N, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clinical lung cancer. Jan 2010;11(1):30-5. doi:10.3816/ CLC.2010.n.005